Prosecution Insights
Last updated: April 19, 2026
Application No. 17/126,349

METHODS AND COMPOSITIONS FOR DETERMINING THE POTENCY OF A THERAPEUTIC CELLULAR COMPOSITION

Non-Final OA §DP
Filed
Dec 18, 2020
Examiner
BELYAVSKYI, MICHAIL A
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Talaris Therapeutics Inc.
OA Round
5 (Non-Final)
64%
Grant Probability
Moderate
5-6
OA Rounds
3y 1m
To Grant
91%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
697 granted / 1091 resolved
+3.9% vs TC avg
Strong +27% interview lift
Without
With
+27.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
77 currently pending
Career history
1168
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
29.0%
-11.0% vs TC avg
§102
9.7%
-30.3% vs TC avg
§112
10.9%
-29.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1091 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . RESPONSE TO APPLICANT’S AMENDMENT 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been saing1.114. Applicant's submission filed on10/22/25 has been hereby entered. 2. Claims 1-8, 10-19, 21, 22 are pending. Claims 1-8,10-19, 21 and 22 read on a method of processing a sample comprising facilitating cells for therapeutic use are under consideration in the instant application. 3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.131(c). A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional, the reply must be complete. MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to https://www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 4. The claims 1-8, 10-19, 21, 22 stand provisionally rejected on the grounds of nonstatutory double patenting of the claims 1-11,43-58 of copending Application No 15/913,520. Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 1-11,43-58 of copending Application No 15/913,520 recited a method of determining the potency of a sample comprising FCs comprising determining the number of FCs in the sample in which ribosomal S6 protein is phosphorylated in response to mitogenic stimulus This is a provisional nonstatutory double patenting rejection because the conflicting claims have not in fact been patented. It is noted that Applicant requested that said rejection to be held in abeyance until allowable subject matter is found. 5. No claim is allowed. 16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/ 272-0840 The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory Emch can be reached on 571/ 272-8149 . The fax number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /MICHAIL A BELYAVSKYI/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Dec 18, 2020
Application Filed
Nov 24, 2023
Non-Final Rejection — §DP
Mar 29, 2024
Response Filed
May 23, 2024
Final Rejection — §DP
Oct 31, 2024
Request for Continued Examination
Nov 05, 2024
Response after Non-Final Action
Feb 21, 2025
Non-Final Rejection — §DP
Jul 31, 2025
Response Filed
Aug 19, 2025
Final Rejection — §DP
Oct 09, 2025
Response after Non-Final Action
Oct 22, 2025
Request for Continued Examination
Oct 23, 2025
Response after Non-Final Action
Feb 26, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599675
NOVEL CONJUGATE OF IMMUNE-STIMULATING IL-2 ANALOG AND PREPARATION METHOD THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12589113
PREPARATION OF A THERAPEUTIC COMPOSITION FOR TREATING AUTOIMMUNE DISEASES
2y 5m to grant Granted Mar 31, 2026
Patent 12584125
METHODS AND USE OF CHIMERIC PROTEINS
2y 5m to grant Granted Mar 24, 2026
Patent 12577581
USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS
2y 5m to grant Granted Mar 17, 2026
Patent 12570959
PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
64%
Grant Probability
91%
With Interview (+27.2%)
3y 1m
Median Time to Grant
High
PTA Risk
Based on 1091 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month